FlandersBio on Twitter

Follow us on Twitter

Archive for August 2013 - News

Archive for August 2013 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

ThromboGenics Business Update H1 2013

30.08.2013

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today issues a business and financial update for the six months ending 30 June, 2013. read more

WELLCOME TRUST AND KU LEUVEN ANNOUNCE COLLABORATION WITH JANSSEN FOR DEVELOPMENT OF DENGUE ANTIVIRAL DRUGS

29.08.2013

Researchers at the University of Leuven (KU Leuven) are joining forces with Janssen Pharmaceuticals Inc. (Janssen) and the Wellcome Trust to discover and develop candidate antiviral drugs for the prevention and treatment of dengue infection. read more

more-efficient-production-of-biofuels-from-waste-with-the-help-of-modified-yeasts

29.08.2013

A significant portion of the petroleum consumed by the transport sector must be replaced in the long term by renewable energy. Therefore, it is of the utmost economic and ecological importance to optimise the production of biofuels from renewable raw materials. Researchers from VIB who are associated with KU Leuven have developed yeast strains that produce bio-ethanol from waste with an unprecedented efficiency. As a result, they are well placed to become important players on a global scale in this burgeoning industry. read more

Oxford BioMedica Announces US$1 million Milestone Payment from Pfizer

28.08.2013

Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announced that a US$1 million milestone payment from Pfizer Inc. has been triggered by the entry of PF-06263507, a 5T4-targeted investigational antibody therapy, into human clinical trials. read more

CARDIO3 BIOSCIENCES ANNOUNCES HALF YEAR FINANCIAL RESULTS AND BUSINESS UPDATE

28.08.2013

The biotechnology company, Cardio3 BioSciences SA (“Cardio3” or the “Company”), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces a business update and its financial results for the six-month period ending 30 June 2013. read more

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

28.08.2013

Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Gimv NV, Adviesbeheer Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print